New Millennium Group LLC Reduces Position in Eli Lilly and Company $LLY

New Millennium Group LLC lessened its stake in Eli Lilly and Company (NYSE:LLY) by 94.4% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 115 shares of the company’s stock after selling 1,940 shares during the period. New Millennium Group LLC’s holdings in Eli Lilly and Company were worth $88,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of LLY. Sumitomo Mitsui Financial Group Inc. purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at about $27,000. Evolution Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $29,000. Steph & Co. raised its position in shares of Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after purchasing an additional 29 shares during the last quarter. Financial Gravity Companies Inc. purchased a new stake in Eli Lilly and Company in the 2nd quarter valued at approximately $31,000. Finally, Bare Financial Services Inc grew its holdings in Eli Lilly and Company by 263.6% during the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on LLY shares. UBS Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 2nd. HSBC restated a “hold” rating and issued a $1,070.00 price target on shares of Eli Lilly and Company in a report on Wednesday, December 10th. Argus increased their price objective on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Daiwa Securities Group raised their target price on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Berenberg Bank boosted their target price on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a report on Tuesday, December 2nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,224.69.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,023.10 on Friday. The stock has a market capitalization of $965.15 billion, a PE ratio of 44.58, a price-to-earnings-growth ratio of 1.19 and a beta of 0.39. The business’s fifty day moving average price is $1,055.22 and its 200 day moving average price is $913.92. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period last year, the company earned $5.32 earnings per share. The firm’s revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is 30.15%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.